Czopik A, McNamee E, Vaughn V, Huang X, Bang I, Clark T
Nat Commun. 2024; 15(1):8042.
PMID: 39271652
PMC: 11399416.
DOI: 10.1038/s41467-024-52113-y.
Alveal M, Mendez A, Garcia A, Henriquez M
Purinergic Signal. 2024; 20(6):595-606.
PMID: 38713328
PMC: 11554604.
DOI: 10.1007/s11302-024-10010-5.
Stepanova M, Aherne C
Cells. 2024; 13(5.
PMID: 38474346
PMC: 10930693.
DOI: 10.3390/cells13050381.
Figarella K, Kim J, Ruan W, Mills T, Eltzschig H, Yuan X
Front Immunol. 2024; 15:1328565.
PMID: 38312838
PMC: 10835146.
DOI: 10.3389/fimmu.2024.1328565.
Poenariu I, Boldeanu L, Ungureanu B, Caragea D, Cristea O, Padureanu V
Biomedicines. 2023; 11(12).
PMID: 38137357
PMC: 10741094.
DOI: 10.3390/biomedicines11123137.
Targeting hypoxia-inducible factors: therapeutic opportunities and challenges.
Yuan X, Ruan W, Bobrow B, Carmeliet P, Eltzschig H
Nat Rev Drug Discov. 2023; 23(3):175-200.
PMID: 38123660
DOI: 10.1038/s41573-023-00848-6.
Ecto-5'-nucleotidase (CD73): an emerging role as prognostic factor in allergic sensitization.
Morello S, Cicala C
Inflamm Res. 2023; 73(1):111-115.
PMID: 38087076
DOI: 10.1007/s00011-023-01820-1.
Mechanism, prevention and treatment of cognitive impairment caused by high altitude exposure.
Chen X, Zhang J, Lin Y, Li Y, Wang H, Wang Z
Front Physiol. 2023; 14:1191058.
PMID: 37731540
PMC: 10507266.
DOI: 10.3389/fphys.2023.1191058.
AR as a Prognostic Marker and a Potential Immunotherapy Target in Human Glioma.
Rafii S, Ghouzlani A, Naji O, Ssi S, Kandoussi S, Lakhdar A
Int J Mol Sci. 2023; 24(7).
PMID: 37047660
PMC: 10095519.
DOI: 10.3390/ijms24076688.
Research Progress on the Mechanism of Intestinal Barrier Damage and Drug Therapy in a High Altitude Environment.
Cheng J, Sun Y, Zhao Y, Guo Q, Wang Z, Wang R
Curr Drug Deliv. 2023; 21(6):807-816.
PMID: 36892115
DOI: 10.2174/1567201820666230309090241.
A Pharmacodynamic Evaluation of the Protective Effects of Roxadustat Against Hypoxic Injury at High Altitude.
Guo Q, Li X, Li W, Wang R, Zhao A, Wang Z
Drug Des Devel Ther. 2023; 17:75-85.
PMID: 36686057
PMC: 9851060.
DOI: 10.2147/DDDT.S390975.
CXCR4 as possible druggable target linking inflammatory bowel disease and Parkinson's disease.
Dogra N, Jakhmola-Mani R, Potshangbam A, Buch S, Katare D
Metab Brain Dis. 2023; 38(3):1079-1096.
PMID: 36656397
DOI: 10.1007/s11011-022-01155-6.
Myeloid hypoxia-inducible factor HIF1A provides cardio-protection during ischemia and reperfusion induction of netrin-1.
Heck-Swain K, Li J, Ruan W, Yuan X, Wang Y, Koeppen M
Front Cardiovasc Med. 2022; 9:970415.
PMID: 36247475
PMC: 9554136.
DOI: 10.3389/fcvm.2022.970415.
The Hypoxia-Adenosine Link during Myocardial Ischemia-Reperfusion Injury.
Ruan W, Ma X, Bang I, Liang Y, Muehlschlegel J, Tsai K
Biomedicines. 2022; 10(8).
PMID: 36009485
PMC: 9405579.
DOI: 10.3390/biomedicines10081939.
The Role of Inflammatory Mediators in Colorectal Cancer Hepatic Metastasis.
Goodla L, Xue X
Cells. 2022; 11(15).
PMID: 35954156
PMC: 9367504.
DOI: 10.3390/cells11152313.
Role of Autophagy Inducers and Inhibitors in Intestinal Barrier Injury Induced by Intestinal Ischemia-Reperfusion (I/R).
Li Y, Zhang P, Zhang J, Bao W, Li J, Wei Y
J Immunol Res. 2022; 2022:9822157.
PMID: 35942211
PMC: 9356893.
DOI: 10.1155/2022/9822157.
Alternative adenosine Receptor activation: The netrin-Adora2b link.
Yuan X, Mills T, Doursout M, Evans S, Melo M, Eltzschig H
Front Pharmacol. 2022; 13:944994.
PMID: 35910389
PMC: 9334855.
DOI: 10.3389/fphar.2022.944994.
Metabolite, protein, and tissue dysfunction associated with COVID-19 disease severity.
Rahnavard A, Mann B, Giri A, Chatterjee R, Crandall K
Sci Rep. 2022; 12(1):12204.
PMID: 35842456
PMC: 9288092.
DOI: 10.1038/s41598-022-16396-9.
Anti-Inflammatory Metabolites in the Pathogenesis of Bacterial Infection.
Urso A, Prince A
Front Cell Infect Microbiol. 2022; 12:925746.
PMID: 35782110
PMC: 9240774.
DOI: 10.3389/fcimb.2022.925746.
The Effects of CD73 on Gastrointestinal Cancer Progression and Treatment.
Sun P, Zheng X, Li X
J Oncol. 2022; 2022:4330329.
PMID: 35620732
PMC: 9130010.
DOI: 10.1155/2022/4330329.